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Small molecule drugs that chemically crosslink double-stranded DNA are commonly used to treat 
cancers that harbor defective DNA repair pathways. For example, interstrand crosslink (ICL)-
inducing agents like cisplatin provide effective treatments for breast and ovarian cancers that lack 
homologous recombination DNA repair factors BRCA1 and BRCA2. However, multiple pathways 
can repair DNA lesions resulting from ICL, which may explain why cancer cells develop 
chemoresistance to certain ICL-inducing agents. Therefore, Drs. Toshiyasu Taniguchi and 
Christopher Kemp of the Human Biology and Public Health Sciences divisions are leading efforts to 
identify novel cancer therapeutics that inhibit diverse ICL repair pathways. In their most recent work, 
former postdoctoral fellow Dr. Yemin Wang and graduate students Jen-Wei Huang and Philamer 
Calses of the Taniguchi Lab discovered a cellular microRNA that downregulates two key factors 
involved in separate, but integrated, ICL repair pathways. Not only does this finding shed light on 
how these different pathways are regulated, but it also provides a novel strategy for targeting 
chemoresistant cancers. 
To find novel therapeutics that downregulate ICL repair pathways, the authors screened small 
molecules for candidates that reduced RAD51 accumulation in the nuclei of cancer cells following 
ICL induction, as accumulation of RAD51 indicates that homologous recombination has been 
activated. In this study, the small molecules being screened were microRNAs, cellular RNA 
molecules that regulate diverse processes with high specificity, and microRNA (miR)-96 was 
identified as a lead candidate. 
Using three different algorithms, Wang and colleagues found that RAD51 and REV1 are predicted 
cellular targets of miR-96, where REV1 is a central component of translesion DNA synthesis that is 
required for cisplatin resistance in certain cancers. Indeed, miR-96 downregulated RAD51 and REV1 
expression in a luciferase reporter assay and improved cancer cell line sensitivity to DNA-damaging 
agents (e.g., cisplatin and PARP inhibitors). The authors then showed that tumor cells pre-treated 
with a lentiviral vector to induce miR-96 overexpression prior to engraftment in an animal tumor 
model exhibited a more significant reduction of tumor growth following cisplatin treatment compared  
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to cancer cells that were treated with cisplatin alone. This suggests that miR-96 holds promise as a 
cancer therapeutic and presents a powerful approach to improve ICL-based cancer treatment. 
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Modified from paper 
Cancer cells overexpressing microRNA (miR)-96 exhibit 
significantly reduced tumor growth following engraftment and 
cisplatin treatment in an in vivo tumor model compared to 
cells expressing a negative control miR (NC + cisplatin), or 
established tumors that express miR-96 but did not receive 
cisplatin treatment (mir-96 + PBS). MiR-96 is small RNA 
molecule that targets two factors in separate, but related, DNA 
repair pathways that are required for cellular resistance to 
DNA-damaging chemotherapy agents. PBS, or phosphate 
buffered saline, is a vehicle control for cisplatin. *, p <0.05, **, 
p <0.01. 
 
